Abeona Therapeutics opens gene therapy manufacturing, immediately starts on expansion – FiercePharma
FiercePharma |
Abeona Therapeutics opens gene therapy manufacturing, immediately starts on expansion
FiercePharma Abeona, with a market cap of $670 million, is working on a series of trials, including a gene therapy for the lysosomal storage disease Sanfilippo B, ABO-101 and ABO-102 for related lysosomal storage disease Sanfilippo A/MPS IIIA, which has shown some … Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio Abeona Therapeutics: What The Latest Data For ABO-102 Foretells? Abeona Therapeutics appoints new additions to board of directors |
